Anke K. T.
- Country
- Germany
- Department
- Brustzentrum
Research Overview
- Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer
- CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Data & Insights
Has run more than one trial at 11 of 308 partner sites.
Specializations
Breast Cancer Focus
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular emphasis on early-stage disease management.
- Early-stage breast cancer treatment
- Hormone receptor-positive disease management
- HER2-negative breast cancer therapy
Their work centers on developing personalized therapeutic approaches for breast cancer patients.
Therapeutic Innovation
The investigator explores innovative treatment combinations involving targeted therapies with endocrine treatment, focusing on optimizing outcomes for breast cancer patients.
- Combined therapy approaches
- Endocrine therapy optimization
- Personalized treatment strategies
Their research examines alternative treatment options to traditional chemotherapy regimens.
Disease Management
The investigator focuses on invasive disease-free survival and long-term patient outcomes in breast cancer treatment.
- Disease-free survival monitoring
- Long-term outcome assessment
- Risk-adjusted therapy approaches
Their work emphasizes dynamic marker-adjusted therapeutic strategies for optimal patient care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.